



## **Edoxaban (tosylate monohydrate)**

**Catalog No: tcsc1333** 

| Available Sizes  |
|--|
| Size: 5mg  |
| Size: 10mg   |
| Size: 50mg   |
| Size: 100mg  |
| Specifications   |
| CAS No:<br>1229194-11-9  |
| Formula:<br>C <sub>31</sub> H <sub>40</sub> CIN <sub>7</sub> O <sub>8</sub> S <sub>2</sub> |
| Pathway:<br>Metabolic Enzyme/Protease  |
| <b>Target:</b><br>Factor Xa  |
| Purity / Grade: >98%   |
| <b>Solubility:</b><br>H2O : 1 mg/mL (1.35 mM; Need ultrasonic)                             |
| Observed Molecular Weight: 738.27  |

## **Product Description**

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention





IC50 Value:

Target: factor Xa

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses[1].

in vitro: Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban[1].

in vivo: Forty-eight subjects, aged 18 to 45 years, received either edoxaban 60 mg once daily  $\times$  7 days (n = 24) or digoxin 0.25 mg twice daily  $\times$  2 days and once daily  $\times$  5 days (n = 24) and then concomitantly for 7 days. Serial blood and urine samples were collected for digoxin and edoxaban concentrations on days 7 and 14. Serial coagulation assays were measured for edoxaban on days 7 and 14. Edoxaban PK parameters demonstrated mild increases in area under the curve and peak concentrations of 9.5% and 15.6%, respectively[2],

Clinical trial: Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans was reported[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!